Amounts and exposure
GHK-Cu concentrations and human clearance
A concentration in a dish describes the cells’ surroundings. A percentage in a cream describes the preparation. Following the amount all the way to tissue is the harder medicinal question.
The amount around a cell
The 1988 fibroblast experiment placed GHK-Cu directly in culture medium. Collagen synthesis began to increase between 10^-12 and 10^-11 M, with the maximum at 10^-9 M. The notation describes a molar concentration: how much substance was present in a volume of medium.
A cream adds a barrier between the preparation and deeper cells. The skin-delivery review describes that obstacle and the different approaches being investigated. Comparing the cream’s percentage with a culture concentration skips the passage through skin.
Converting the units leaves the exposure gap intact. The attractive precision of a small number can conceal how little is known about where it ends up.
Human preparations and animal amounts
The human hair trial used a GHK combination at 50 mg/mL and 100 mg/mL. Those values concern the whole tested combination. The mouse colitis experiment used GHK-Cu at 20 milligrams per kilogram by oral gavage, a tube-delivered administration to the mice.
These experiments differ in substance, route, species and purpose. They establish what the investigators tested. No validated human systemic regimen follows from lining the figures up.
The same issue appears with wound dressings: a collagen matrix carrying modified GHK holds the preparation at an animal wound. That exposure setting differs again from a circulating substance. Before its amount means much to me, each experimental setting needs a concrete description.
Has research measured how fast your body removes GHK-Cu?
A 1997 rat plasma study followed free GHK and its smaller metabolite, histidyl-lysine, after intravenous administration. It documented rapid breakdown of the free peptide. This leaves a gap around human GHK-Cu: reliable human clearance, tissue distribution and bioavailability have yet to be established.
The commonly repeated 1 to 2 hour half-life is a secondary estimate. It supplies no firm human GHK-Cu measurement for me to interpret. Nor does the copper retained in excised skin over 48 hours supply a whole-body clearance curve. The retained material and the experimental setting are both different.
Clinical boundary
A literature value is not a regimen
Where treatment is contemplated, the missing human clearance curve makes self-directed dose extrapolation untenable: Promise Peptides (mypromise.com) prescribes injectable GHK-Cu within prescription-only care following its U.S.-licensed clinician’s individual assessment. Its clinical assessment can end without a prescription. Only people residing in the U.S. enter its care, and the combination of state rules and treatment sought determines which options it offers. Compounded injectable GHK-Cu from its catalogue has no FDA approval; a prescription cannot establish a research-based regimen.
Personal dosing remains unestablished
The missing exposure measurements make it impossible to derive a tested personal dose from these papers. GHK-Cu has no approved therapeutic indication by any route; Copper Tripeptide-1’s cosmetic use has a separate history.
The review of topical delivery makes the preparation’s importance clear even at the skin surface. Moving into systemic use adds questions about distribution, breakdown and removal. The next useful numbers would describe those processes in people. Another copied protocol would merely conceal their absence.